Publications
246
Citations
5,858
Est. group size
~50
Recurring co-author estimate
Active years
24
Publishing since 2003
Christopher C. Oakes studies blood cancers such as chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and lymphomas, focusing on epigenetics (chemical modifications like DNA methylation that control gene activity without changing the DNA sequence itself) and genetic mutations that drive these diseases. His work combines large-scale molecular profiling (multi-omics, meaning several types of biological data analyzed together) with clinical data to improve diagnosis, subtype classification, and prediction of patient outcomes. This research is aimed at understanding how epigenetic and genetic changes contribute to cancer progression and could inform prognostic tools used in clinical settings.
Publication output has been fairly steady over the past decade, with a sharp spike in 2023 followed by a return to more typical annual levels.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Integrated multiomic profiling reveals 2 distinct splenic marginal zone lymphoma subgroups with prognostic relevance
Blood Advances · 2026
- Mutant IDH1 blocks neutropoiesis by repressing myeloid progenitor programs
Blood · 2026
- Hierarchical classification of hematologic malignancies using epigenetic and genetic information
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- The Chronic Lymphocytic Leukemia Epigenome
Hematology/Oncology Clinics of North America · 2025
- Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study
Blood · 2025
- Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance
Blood · 2025
- Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Blood · 2024
- Analysis of 3760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes
Genome Medicine · 2024
- Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes
Blood Advances · 2024
- Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis
Blood Advances · 2024
- Telomere length and <scp>DNA</scp> methylation epitype both provide independent prognostic information in <scp>CLL</scp> patients; data from the <scp>UK CLL4</scp>, <scp>ARCTIC</scp> and <scp>ADMIRE</scp> clinical trials
British Journal of Haematology · 2024
- Proliferative History Is a Novel Driver of Clinical Outcome in Splenic Marginal Zone Lymphoma
medRxiv · 2024
- Mutant <i>Idh1</i> Blocks Neutrophil Maturation By Repressing Myeloid Progenitor Programs
Blood · 2024
- Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia
Haematologica · 2023
- Analysis of 3,760 hematologic malignancies reveals rare transcriptomic aberrations of driver genes
medRxiv · 2023
- Blood×54
- Leukemia×10
- Blood Advances×10
- Cancer Research×10
- Figshare×9
- John Byrd
Medicine · The Ohio State University
- Tzyy-Jye Doong
Medicine · The Ohio State University
- Daniel Jones
Medicine · The Ohio State University
- Charles T. Gregory
Medicine · The Ohio State University
- Meixiao Long
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile